Calculatin the Effective Intravenous Heparin Dose: Comparison between Lean and Actual Body Weight-Based Dosing in Obese Patients

Background: Despite the availability of newer anticoagulants, unfractionated heparin remains a mainstay anticoagulant for atrial fibrillation, acute coronary syndrome with or without percutaneous intervention, treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Aim of Study: The aim of this study is to investigate if intravenous heparin dosing based on lean body weight (LBW) of obese patients would be safe and effective in achieving activated partial thromboplastin time (APTT) within 24 hours compared to the usual practice. Patients and Methods: This is a case-control study conducted in Cardiology Department Sammanaud General Hospital from May 2017 to May 2018 to investigate if intravenous heparin dosing based on LBW of obese patients would be safe and effective in achieving target APTT within 24 hours compared to the usual practice. The study included 50 obese patients with a diagnosis of atrial fibrillation, suspected or confirmed deep venous thrombosis or pulmonary embolism, unstable angina or Non ST elelvation myocardial infarction with hemodynamic stability, or peripheral vascular disease. Patients aged >18 years randomized into two groups (1) and (2). Results: Studies found that unfractionated heparin dosage adjustments based on the patient's LBW provided therapeutic anticoagulation more rapidly and safely, but protocols based on total body weight increase the risk of a supra-therapeutic PTT. Conclusion: Unfractionated heparin remains a mainstay anticoagulant for atrial fibrillation, acute coronary syndrome with or without percutaneous intervention, treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. As lean body weight contributes to approximately 99% of a drug's clearance, it is useful for guiding dosing in obesity. These findings may enhance the utility of LBW as body descriptor instead of TBW in calculating the effective doses of UFH in treatment of thromboembolic disorders. Correspondence to: Dr. Amr F. Abo El Fotouh, The Department of Cardiology, National Heart Institute and Faculty of Medicine, Mansoura University

[1]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[2]  T. Baglin,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[3]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[4]  B. Green,et al.  The effects of obesity on drug pharmacokinetics in humans , 2011, Expert opinion on drug metabolism & toxicology.

[5]  Darrell R. Abernethy,et al.  Effect of Obesity on the Pharmacokinetics of Drugs in Humans , 2010, Clinical pharmacokinetics.

[6]  K. McAllen,et al.  Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. , 2008, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[7]  Stephen B. Duffull,et al.  Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.

[8]  M. Pai,et al.  The Origin of the “Ideal” Body Weight Equations , 2000, The Annals of pharmacotherapy.

[9]  Robert Raschke,et al.  The Weight-based Heparin Dosing Nomogram Compared with a Standard Care Nomogram , 1993, Annals of Internal Medicine.

[10]  M. Rivey,et al.  Pharmacy-managed, weight-based heparin protocol. , 1993, American journal of hospital pharmacy.

[11]  G. Raskob,et al.  Optimal therapeutic level of heparin therapy in patients with venous thrombosis. , 1992, Archives of internal medicine.

[12]  J. Martinoff,et al.  Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol. , 1985, American journal of hospital pharmacy.